Article Text

PDF

Tolerance to somatostatin analogue in a preterm infant with islet cell dysregulation syndrome.
  1. J M Hawdon,
  2. M P Ward Platt,
  3. W H Lamb,
  4. A Aynsley-Green
  1. Department of Child Health, Princess Mary Hospital, Newcastle upon Tyne.

    Abstract

    An infant of 31 weeks' gestation presented with refractory neonatal hypoglycaemia secondary to islet cell dysregulation. Treatment was started with somatostatin analogue and his glycaemic control improved initially. Tolerance developed, however, in that the dose required to maintain control increased by a factor of 40. The infant subsequently underwent pancreatectomy. It is safe to use somatostatin analogue in a preterm infant, but tolerance to the drug rapidly develops.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.